Strategic Focus Cleave Therapeutics targets VCP/p97 as a novel cancer and neurodegenerative disease pathway, presenting a focused opportunity for partnerships with biotech firms and academic collaborators seeking to leverage protein homeostasis targets in oncology and neurology.

Clinical Pipeline Lead candidate CB-5339 is an oral, selective VCP/p97 inhibitor with ongoing Phase 1 studies in AML and potential expansion into solid tumors via NCI collaboration, signaling a path for co-development deals, licensing, or strategic financing.

Collaborative Momentum Existing and potential partnerships with the National Cancer Institute and academia, plus prior collaborations (Jazz Pharmaceuticals, CASI) indicate a receptive ecosystem for collaboration, joint development, and upfront/ milestone financing.

Asset Reallocation Past divestiture of preclinical assets to Eikon Therapeutics suggests a strategic willingness to monetize non-core assets, creating avenues for buying, licensing, or milestone-based partnerships around core VCP/p97 programs.

Financial Terrain With a funded runway and modest revenue alongside a sizable funding pool, Cleave presents opportunities for strategic investors or corporates seeking early-stage oncology or neurodegeneration platforms with scalable collaboration potential.